Please Note: Amanat Acquisition is a stock-only SPAC IPO – an exception to the more prevalent SPAC IPO structure as a unit offering with each unit consisting of a share of stock plus a warrant or a right – or both.)

(Incorporated in the Cayman Islands)

We are a newly organized blank check company. We intend to focus our search for a suitable acquisition target on the healthcare sector, with an emphasis on companies involved in biotech or the life sciences.

Sandeep Kulkarni, M.D., is our CEO. He is also the CEO of Zura Bio, a clinical-stage biotech company developing novel medicines to treat patients with serious and debilitating autoimmune and inflammatory diseases. Dr. Kulkarni previously was the CEO of Tourmaline Bio, which he co-founded and led through its acquisition by Novartis in October 2025.

(Note: Amanat Acquisition Corp. priced its small SPAC IPO – just 7.5 million shares – at $10.00 each – to raise $75 million, the company announced on Tuesday, May 19, 2026. Worth Noting: Amanat Acquisition Corp. is a stock-only blank-check IPO. In contrast, most SPAC IPOs are unit offerings with each unit consisting of a share of stock plus a warrant or a right – a combination of a warrant and a right with a share of stock.)